CGON

79.4702.97%
VE

Victor E. Tong

Independent Director

Mr. Victor E. Tong, Jr. is a Managing Director at Decheng Capital LLC and has been with the firm since its inception. He also served as a Partner at the firm. Mr. Tong focuses on investments in biotechnology and medical technology companies in the US and China. He serves as an Independent Director of Aardvark Therapeutics, Inc. since May 2024, as a Director at CG Oncology, Inc. since July 2023, as Non-Executive Director at Hummingbird Bioscience Pte. Ltd. since April 26, 2019, and as a Director at SentreHEART, Inc. since August 12, 2015. Mr. Tong also serves as a Director of Cellares Corp., Harton Therapeutics, and Watchmaker Genomics, Inc. He is a Partner and Director of LevitasBio, Inc. and serves on the boards of Cue Health, AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Sema4, and Take2. Previously, Mr. Tong served as Chairman at ReadCoor. He also held board positions at Terns Pharmaceuticals, Nalu Medical, Inc., GeneWEAVE Biosciences, and Cirina. He served as a Board Observer at Nevro. Prior to joining Decheng, he was a Principal at Bay City Capital LLC, where he also served as an Analyst. Before that, he was an Investment Banker with Morgan Stanley. He was an entrepreneur at Hana Biosciences and began his career as a research assistant at Incyte Genomics in 1999. At Bay City Capital LLC, Mr. Tong played a key role in several transactions, including the firm's investments in Ion Torrent Systems and ZymoGenetics, and was actively involved in a number of its portfolio companies, including GenturaDx, Hyperion Therapeutics and NextWave Pharmaceuticals. He also assisted with management of several of the firm's publicly traded portfolio companies, including Cadence Pharmaceuticals and EnteroMedics. At Morgan Stanley, he advised biotechnology, pharmaceutical, medical device and diagnostic companies on initial public offerings and specialized in strategic advisory work. At Hana Biosciences, he was responsible for pipeline development, licensing and product launch for cancer products. He is also an author of a publication in Pharmaceutical Executive. Mr. Tong holds a B.A. in Molecular and Cell Biology and a B.S. in Business Administration from the University of California, Berkeley.

Positions